Advaxis licenses ISG15 tumor antigen from University of Pennsylvania
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has exclusively licensed the use of antigen ISG15 in Advaxis' Lm-LLO based immunotherapies from the University of Pennsylvania.